September 15, 1996
Since the end of the Cold War, U.S. scientists have had to knock on corporate doors for the research funds once lavished on them by a government eager to maintain American technological dominance. The resulting corporate-academic partnership has produced research projects of considerable value, but not without sometimes generating bitter conflict between scientists and business.
August 26, 1986 |
In what appears to be the first patent suit involving gene-splicing technology, a Thousand Oaks firm is asking a federal judge to overturn the only U.S. patents issued for a promising new anti-cancer substance called interleukin-2. The suit was filed by Amgen in U.S. District Court in San Francisco against Cetus Corp., an Emeryville, Calif., firm that holds the patents. Cetus supplied the drug, also known as IL-2, used by Dr. Steven A.